Updates in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Nov 9, 2021

This publication reviews the role of Bruton tyrosine kinase inhibitors, particularly when treating patients with agents that are to be taken continually and for an indefinite period of time, for the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia, recapping key insights from a scientific interchange & workshop.

Related Content